RECRUITING

Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.

Official Title

Feasibility and Safety of Single Dose Ketamine for Acutely Suicidal Patients in the Emergency Department

Quick Facts

Study Start:2024-05-01
Study Completion:2025-04
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06085937

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Acutely Suicidality ("yes" answer to any of items 4 or 5 on C-SSRS "Suicidal Ideation" category)
  2. * Require inpatient stabilization for SI or actions based on clinical observation and interview
  3. * Are accepted for psychiatric stabilization at the University of Kansas Medical Center's Strawberry Hill campus
  4. * Have a Glasgow Coma Score (GCS) of 15
  5. * Age 18-65
  1. * Current or past history of psychosis
  2. * Current or recent (past 4 weeks) symptoms of mania/hypomania as defined by Young Mania Rating Scale (YRMS) score of 12 or greater
  3. * History of ketamine use disorder
  4. * History of liver transplant
  5. * Pregnancy or breastfeeding
  6. * Imprisonment or inability to consent
  7. * Positive urine drug screen or serum alcohol level
  8. * Hypertension (SBP \> 160 or DBP \> 100 before administration of ketamine)
  9. * Hypotension (SBP \< 90)
  10. * Presence of acute medical condition requiring admission to medical service
  11. * Allergy, intolerance, or previous adverse reaction to ketamine
  12. * Patient has 8+ lifetime ketamine exposures
  13. * The treating physician determines that the patient is not a good candidate for the study (e.g. medical condition/procedure, medication that would contradindicate ketamine treatment)

Contacts and Locations

Study Contact

Lindsay Maguire, MD
CONTACT
913-588-3580
lmaguire@kumc.edu
Lucas Lemar
CONTACT
llemar@kumc.edu

Study Locations (Sites)

University of Kansas Strawberry Hill Campus
Kansas City, Kansas, 66101
United States
University of Kansas Medical Center Emergency Department
Kansas City, Kansas, 66160
United States

Collaborators and Investigators

Sponsor: Lindsay Maguire, MD

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-01
Study Completion Date2025-04

Study Record Updates

Study Start Date2024-05-01
Study Completion Date2025-04

Terms related to this study

Additional Relevant MeSH Terms

  • Suicide
  • Suicidal Ideation
  • Depression